By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators discuss new findings in Biotechnology. According to news reporting originating in Tokushima, Japan, by NewsRx journalists, research stated, "Triple negative breast cancer (TNBC) has a poor outcome due to the lack of beneficial therapeutic targets. To clarify the molecular mechanisms involved in the carcinogenesis of TNBC and to identify target molecules for novel anticancer drugs, we analyzed the gene expression profiles of 30 TNBCs as well as 13 normal epithelial ductal cells that were purified by laser-microbeam microdissection."
The news reporters obtained a quote from the research from the University of Tokushima, "We identified 301 and 321 transcripts that were significantly upregulated and downregulated in TNBC, respectively. In particular, gene expression profile analyses of normal human vital organs allowed us to identify 104 cancer-specific genes, including those involved in breast carcinogenesis such as NEK2, PBK and MELK. Moreover, gene annotation enrichment analysis revealed prominent gene subsets involved in the cell cycle, especially mitosis. Therefore, we focused on cell cycle regulators, asp (abnormal spindle) homolog, microcephaly-associated (Drosophila) (ASPM) and centromere protein K (CENPK) as novel therapeutic targets for TNBC. Small-interfering RNA-mediated knockdown of their expression significantly attenuated TNBC cell viability due to G1 and G2/M cell cycle arrest."
According to the news reporters, the research concluded: "Our data will provide a better understanding of the carcinogenesis of TNBC and could contribute to the development of molecular targets as a treatment for TNBC patients."
For more information on this research see: Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. International Journal of Oncology, 2013;42(2):478-506 (see also Biotechnology).
Our news correspondents report that additional information may be obtained by contacting M. Komatsu, Division of Genome Medicine, Institute for Genome Research, The University of Tokushima, Tokushima, Japan. Additional authors for this research include T. Yoshimaru, T. Matsuo, K. Kiyotani, Y. Miyoshi, T. Tanahashi, K. Rokutan, R. Yamaguchi, A. Saito, S. Imoto, S. Miyano, Y. Nakamura, M. Sasa, M. Shimada and T. Katagiri.
Keywords for this news article include: Asia, Biotechnology, Japan, Genetics, Oncology, Tokushima, Therapeutics, Breast Cancer, Carcinogenesis, Women's Health, Cancer Gene Therapy.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC